WAVE Life Sciences (WVE) Projected to Post Quarterly Earnings on Thursday

WAVE Life Sciences (NASDAQ:WVE) is projected to issue its Q2 2026 results before the market opens on Thursday, July 30th. Analysts expect the company to post earnings of ($0.31) per share and revenue of $7.45 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, July 30, 2026 at 8:30 AM ET.

WAVE Life Sciences (NASDAQ:WVE) last issued its earnings results on Wednesday, April 29th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.34) by $0.21. The company had revenue of $38.25 million during the quarter, compared to the consensus estimate of $8.45 million. WAVE Life Sciences had a negative return on equity of 56.76% and a negative net margin of 255.70%. On average, analysts expect WAVE Life Sciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

WAVE Life Sciences Price Performance

NASDAQ:WVE opened at $5.92 on Tuesday. WAVE Life Sciences has a one year low of $5.02 and a one year high of $21.73. The company has a market cap of $1.14 billion, a PE ratio of -5.58 and a beta of -1.29. The firm has a 50-day moving average of $6.02 and a 200-day moving average of $9.19.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on WVE. Canaccord Genuity Group cut their price target on shares of WAVE Life Sciences from $52.00 to $43.00 and set a “buy” rating on the stock in a report on Thursday, April 30th. Wall Street Zen raised shares of WAVE Life Sciences from a “strong sell” rating to a “hold” rating in a research report on Saturday, May 2nd. Citigroup cut their target price on WAVE Life Sciences from $30.00 to $24.00 and set a “buy” rating on the stock in a research note on Monday, May 4th. New Street Research set a $13.00 target price on WAVE Life Sciences in a report on Thursday, June 11th. Finally, Zacks Research raised WAVE Life Sciences from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 21st. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $26.41.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in WVE. GSK plc purchased a new stake in shares of WAVE Life Sciences during the 4th quarter worth approximately $310,177,000. Adage Capital Partners GP L.L.C. lifted its stake in WAVE Life Sciences by 20.0% in the second quarter. Adage Capital Partners GP L.L.C. now owns 15,016,500 shares of the company’s stock valued at $97,607,000 after purchasing an additional 2,500,000 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its stake in WAVE Life Sciences by 83.1% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 7,407,372 shares of the company’s stock valued at $125,927,000 after purchasing an additional 3,362,880 shares during the last quarter. Darwin Global Management Ltd. bought a new position in WAVE Life Sciences during the fourth quarter valued at $125,168,000. Finally, Federated Hermes Inc. grew its holdings in WAVE Life Sciences by 26.5% during the fourth quarter. Federated Hermes Inc. now owns 4,744,520 shares of the company’s stock valued at $80,657,000 after purchasing an additional 993,827 shares during the period. 89.73% of the stock is currently owned by hedge funds and other institutional investors.

WAVE Life Sciences Company Profile

WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.

The company’s pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington’s disease, as well as early-stage cardiovascular and liver indications.